0001209191-20-023807.txt : 20200407 0001209191-20-023807.hdr.sgml : 20200407 20200407172235 ACCESSION NUMBER: 0001209191-20-023807 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200403 FILED AS OF DATE: 20200407 DATE AS OF CHANGE: 20200407 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hirsch Stanley CENTRAL INDEX KEY: 0001727864 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38356 FILM NUMBER: 20780479 MAIL ADDRESS: STREET 1: C/O FOAMIX PHARMACEUTICALS LTD. STREET 2: 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK CITY: REHOVOT STATE: L3 ZIP: 76704 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Menlo Therapeutics Inc. CENTRAL INDEX KEY: 0001566044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 453757789 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 BUSINESS PHONE: 800-775-7936 MAIL ADDRESS: STREET 1: 520 U.S. HIGHWAY 22, SUITE 204 CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Menlo Therapeutics, Inc. DATE OF NAME CHANGE: 20170728 FORMER COMPANY: FORMER CONFORMED NAME: Tigercat Pharma, Inc. DATE OF NAME CHANGE: 20130104 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-03 0 0001566044 Menlo Therapeutics Inc. MNLO 0001727864 Hirsch Stanley 520 U.S. HIGHWAY 22, SUITE 204 BRIDGEWATER NJ 08807 1 0 0 0 Common Stock 2020-04-03 4 A 0 63844 A 130107 D Common Stock 2020-04-03 4 A 0 220496 A 328609 I See footnote Common Stock 2020-04-03 4 A 0 71303 A 201410 D As disclosed by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on April 6, 2020, following the receipt of certain clinical trial results, Menlo Therapeutics Inc. ("Menlo") issued additional shares of its common stock pursuant to certain contingent stock rights ("CSRs") issued in connection with the March 9, 2020 merger (the "Merger") of Menlo and Foamix Pharmaceuticals Ltd. ("Foamix"), including pursuant to CSRs held by the Reporting Person. The issuance of shares pursuant to the CSRs resulted in an adjustment to the effective exchange ratio applicable to the Merger, from 0.5924 to 1.8006 (the "Final Exchange Ratio"). Menlo derivative securities issued in exchange for Foamix derivative securities in connection with the Merger were also adjusted pursuant to their terms to give effect to the Final Exchange Ratio. The transactions reported in these line items reflect the additional shares and restricted stock unit (continued in footnote 2) (continued from footnote 1) awards that were received by the reporting person as a result of the foregoing. Securities are held by ZEAS Technology and Science Management Ltd., a company beneficially owned by Stanley Hirsch. Represents restricted stock unit awards, each of which by its terms represents a contingent right to receive one share of common stock of Menlo. In connection with the events described in footnote 1, each option to purchase shares of Menlo common stock that was acquired by the Reporting Person in connection with the Merger (as reported on the Form 4 filed by the Reporting Person on March 11, 2020) has been adjusted pursuant to its terms. /s/ Mutya Harsch, attorney-in-fact for Stanley Hirsch 2020-04-07